Dr Reddys Laboratories (RDY) EBITDA (2009 - 2023)

Dr Reddys Laboratories (RDY) has reported EBITDA for 15 consecutive years, with $215.0 million the latest figure, recorded in Q2 2023.

• Quarterly EBITDA changed N/A year-over-year to $215.0 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $200000.7 billion (changed N/A YoY) and the FY2026 annual result came in at $539.0 million, down 35.99% from the prior year.
• EBITDA eased to $215.0 million in Q2 2023 per RDY's latest filing, from $260.0 million in the prior quarter.
• Over the last five years, EBITDA for RDY reached as high as $200000.0 billion in Q3 2022 and fell as low as -$82.0 million in Q3 2019.
• A 5-year average of $16666.8 billion and a median of $113.0 million in 2019 frame the typical range for EBITDA.
• The largest YoY upside for EBITDA was 69.7% in 2019 against a maximum downside of 198.8% in 2019.
• Year by year, EBITDA stood at -$82.0 million in 2019, then advanced by 2.44% to -$80.0 million in 2020, then surged by 303.75% to $163.0 million in 2021, then grew by 22.09% to $199.0 million in 2022, then gained by 8.04% to $215.0 million in 2023.
• According to Business Quant data, EBITDA over the past three periods registered $215.0 million, $260.0 million, and $199.0 million for Q2 2023, Q1 2023, and Q4 2022 respectively.